FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753805759> ?p ?o ?g. }

• W2753805759 endingPage "2336" @default.
• W2753805759 startingPage "2322" @default.
• W2753805759 abstract "De novo in-frame deletions and duplications in the SPTAN1 gene, encoding the non-erythrocyte αII spectrin, have been associated with severe West syndrome with hypomyelination and pontocerebellar atrophy. We aimed at comprehensively delineating the phenotypic spectrum associated with SPTAN1 mutations. Using different molecular genetic techniques, we identified 20 patients with a pathogenic or likely pathogenic SPTAN1 variant and reviewed their clinical, genetic and imaging data. SPTAN1 de novo alterations included seven unique missense variants and nine in-frame deletions/duplications of which 12 were novel. The recurrent three-amino acid duplication p.(Asp2303_Leu2305dup) occurred in five patients. Our patient cohort exhibited a broad spectrum of neurodevelopmental phenotypes, comprising six patients with mild to moderate intellectual disability, with or without epilepsy and behavioural disorders, and 14 patients with infantile epileptic encephalopathy, of which 13 had severe neurodevelopmental impairment and four died in early childhood. Imaging studies suggested that the severity of neurological impairment and epilepsy correlates with that of structural abnormalities as well as the mutation type and location. Out of seven patients harbouring mutations outside the α/β spectrin heterodimerization domain, four had normal brain imaging and three exhibited moderately progressive brain and/or cerebellar atrophy. Twelve of 13 patients with mutations located within the spectrin heterodimer contact site exhibited severe and progressive brain, brainstem and cerebellar atrophy, with hypomyelination in most. We used fibroblasts from five patients to study spectrin aggregate formation by Triton-X extraction and immunocytochemistry followed by fluorescence microscopy. αII/βII aggregates and αII spectrin in the insoluble protein fraction were observed in fibroblasts derived from patients with the mutations p.(Glu2207del), p.(Asp2303_Leu2305dup) and p.(Arg2308_Met2309dup), all falling in the nucleation site of the α/β spectrin heterodimer region. Molecular modelling of the seven SPTAN1 amino acid changes provided preliminary evidence for structural alterations of the A-, B- and/or C-helices within each of the mutated spectrin repeats. We conclude that SPTAN1-related disorders comprise a wide spectrum of neurodevelopmental phenotypes ranging from mild to severe and progressive. Spectrin aggregate formation in fibroblasts with mutations in the α/β heterodimerization domain seems to be associated with a severe neurodegenerative course and suggests that the amino acid stretch from Asp2303 to Met2309 in the α20 repeat is important for α/β spectrin heterodimer formation and/or αII spectrin function." @default.
• W2753805759 created "2017-09-15" @default.
• W2753805759 creator A5002988240 @default.
• W2753805759 creator A5007561965 @default.
• W2753805759 creator A5008944813 @default.
• W2753805759 creator A5009870571 @default.
• W2753805759 creator A5012075674 @default.
• W2753805759 creator A5012906944 @default.
• W2753805759 creator A5015827592 @default.
• W2753805759 creator A5017941068 @default.
• W2753805759 creator A5018356826 @default.
• W2753805759 creator A5024518420 @default.
• W2753805759 creator A5025164290 @default.
• W2753805759 creator A5028906199 @default.
• W2753805759 creator A5033226852 @default.
• W2753805759 creator A5034813741 @default.
• W2753805759 creator A5038427804 @default.
• W2753805759 creator A5040167428 @default.
• W2753805759 creator A5040752773 @default.
• W2753805759 creator A5040872292 @default.
• W2753805759 creator A5042463561 @default.
• W2753805759 creator A5045173481 @default.
• W2753805759 creator A5048859419 @default.
• W2753805759 creator A5052522766 @default.
• W2753805759 creator A5054735627 @default.
• W2753805759 creator A5055323325 @default.
• W2753805759 creator A5057534469 @default.
• W2753805759 creator A5057904561 @default.
• W2753805759 creator A5061679588 @default.
• W2753805759 creator A5063894541 @default.
• W2753805759 creator A5064882987 @default.
• W2753805759 creator A5067722631 @default.
• W2753805759 creator A5071894755 @default.
• W2753805759 creator A5075037256 @default.
• W2753805759 creator A5075161655 @default.
• W2753805759 creator A5080876994 @default.
• W2753805759 creator A5082917975 @default.
• W2753805759 creator A5083096431 @default.
• W2753805759 creator A5083154542 @default.
• W2753805759 creator A5085467135 @default.
• W2753805759 creator A5085795324 @default.
• W2753805759 creator A5087910719 @default.
• W2753805759 creator A5088232648 @default.
• W2753805759 creator A5090027115 @default.
• W2753805759 creator A5090976177 @default.
• W2753805759 creator A5091379651 @default.
• W2753805759 date "2017-08-24" @default.
• W2753805759 modified "2023-10-18" @default.
• W2753805759 title "Delineating SPTAN1 associated phenotypes: from isolated epilepsy to encephalopathy with progressive brain atrophy" @default.
• W2753805759 cites W1607630920 @default.
• W2753805759 cites W1673813955 @default.
• W2753805759 cites W1968860221 @default.
• W2753805759 cites W1969018535 @default.
• W2753805759 cites W1970864605 @default.
• W2753805759 cites W1979081257 @default.
• W2753805759 cites W1995469989 @default.
• W2753805759 cites W2000197503 @default.
• W2753805759 cites W2016194769 @default.
• W2753805759 cites W2016728649 @default.
• W2753805759 cites W2042096171 @default.
• W2753805759 cites W2045392412 @default.
• W2753805759 cites W2051978340 @default.
• W2753805759 cites W2053567778 @default.
• W2753805759 cites W2060809301 @default.
• W2753805759 cites W2060849333 @default.
• W2753805759 cites W2061198767 @default.
• W2753805759 cites W2066032422 @default.
• W2753805759 cites W2068520568 @default.
• W2753805759 cites W2069205093 @default.
• W2753805759 cites W2073032316 @default.
• W2753805759 cites W2078603373 @default.
• W2753805759 cites W2085221852 @default.
• W2753805759 cites W2102398250 @default.
• W2753805759 cites W2111396504 @default.
• W2753805759 cites W2132629607 @default.
• W2753805759 cites W2146894481 @default.
• W2753805759 cites W2168397700 @default.
• W2753805759 cites W2169732227 @default.
• W2753805759 cites W2201284016 @default.
• W2753805759 cites W2233252933 @default.
• W2753805759 cites W2270303516 @default.
• W2753805759 cites W2278487942 @default.
• W2753805759 cites W2281890638 @default.
• W2753805759 cites W2340593234 @default.
• W2753805759 cites W2514154970 @default.
• W2753805759 cites W569341862 @default.
• W2753805759 doi "https://doi.org/10.1093/brain/awx195" @default.
• W2753805759 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6248409" @default.
• W2753805759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29050398" @default.
• W2753805759 hasPublicationYear "2017" @default.
• W2753805759 type Work @default.
• W2753805759 sameAs 2753805759 @default.
• W2753805759 citedByCount "65" @default.
• W2753805759 countsByYear W27538057592018 @default.
• W2753805759 countsByYear W27538057592019 @default.
• W2753805759 countsByYear W27538057592020 @default.
• W2753805759 countsByYear W27538057592021 @default.
• W2753805759 countsByYear W27538057592022 @default.

• next